---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-24-000183"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:42:04.556085+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunovant announces five IND clearances for IMVT-1402 and plans to initiate registrational trials by March 2025

## Summary
- Five INDs cleared for IMVT-1402 across therapeutic areas including Graves' disease and rheumatoid arthritis.
- Proof-of-concept data from batoclimab in Graves' disease showed 60% response rate at week 2; registrational trial for IMVT-1402 expected by year-end 2024.
- Initiation of potentially registrational trial for IMVT-1402 in difficult-to-treat RA expected by March 31, 2025.
- Batoclimab trials in MG and CIDP fully enrolled; data disclosures by March 31, 2025.
- Appointed Melanie Gloria as COO effective Nov 18, 2024; net loss $109.1M for quarter ended Sept 30, 2024.

## SEC filing metadata
- accession: 0001764013-24-000183
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000183/0001764013-24-000183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000183/imvt-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-24-000183
- JSON: https://secwatch.observer/filing/0001764013-24-000183.json
- Plain text: https://secwatch.observer/filing/0001764013-24-000183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.